Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

United States

Moffit Cancer Center, Tampa, Florida

University of Illinois Cancer Center, Chicago, Illinois

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

University of Iowa Hospitals and Clinics, Iowa City, Iowa

University of Minnesota, Minneapolis, Minnesota

University of Nebraska Medical Center, Omaha, Nebraska

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Providence Health & Services - Oregon, Portland, Oregon

Penn State Cancer Institute, Hershey, Pennsylvania

University of Virginia Health System, Charlottesville, Virginia

Virginia Commonwealth University, Richmond, Virginia

Univeristy of Wisconsin, Madison, Wisconsin